Marker Therapeutics, Inc.

Monthly Archives: February 2020

Marker Therapeutics to Present at Two Upcoming Investor Conferences

Marker Therapeutics, Inc. (NASDAQ:MRKR) today announced that its President and Chief Executive Officer, Peter L. Hoang, will present at two upcoming investor conferences. Live webcasts of the presentations will be accessible from the investors section of the company’s website at markertherapeutics.com and will be available for replay following the event.

Read More

Marker Therapeutics Announces Update to its Clinical Program in AML

Marker Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on Marker’s planned trial investigating safety and efficacy of its novel MultiTAA T cell therapy in patients with post-transplant acute myeloid leukemia (AML).

Read More